$UNCY

Unicycive Therapeutics, Inc.

Unicycive Therapeutics is a clinical-stage biotechnology company developing therapies for kidney disease. Its two product candidates are oxylanthanum carbonate (OLC), an investigational phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for acute kidney injury. OLC is designed as a tablet swallowed whole at mealtimes, while UNI-494 has completed a Phase I clinical study in healthy volunteers. Unicycive licenses technologies and drug candidates, then pursues their development, regulatory approval and commercialization in global markets. It is seeking U.S. approval for OLC and is building commercial infrastructure focused on nephrology, including specialty sales, dialysis organization relationships, distribution and reimbursement support. The company aims to develop and commercialize treatments for patients with kidney disease and plans to partner with global biopharmaceutical companies outside the U.S. Unicycive is headquartered in Mountain View, California.

3
2
2

No SEC Form 4 filings for $UNCY in the last 30 days.

See all $UNCY insider activity →
Med

Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities

Unicycive Therapeutics reported a Q3 2026 net loss of $7.0 million, or $0.25 per share, with $59 million in cash. The FDA accepted its OLC NDA resubmission, setting a March 25, 2027 PDUFA date. The company expects its cash runway to extend beyond 2027, including potential OLC launch costs. Research and development expenses decreased to $2.2 million from $3.0 million a year earlier, while general and administrative expenses increased to $6.6 million from $4.4 million.

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update - New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (

UNCY sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning UNCY (Unicycive Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 2 bearish.

Recent UNCY coverage spans regulation, financial news and market movers.

What's driving UNCY

  • FDA acceptance of the OLC NDA resubmission and a defined PDUFA date should reduce near-term regulatory uncertainty, supporting risk-on positioning into 2027.

    tradingview.com · Nov 16, 2026

  • The NDA acceptance removes a regulatory hurdle, potentially boosting the stock if approval follows; Q3 loss may temper short‑term sentiment.

    SEC EDGAR 8-K · Nov 16, 2026

  • The lawsuit introduces legal and regulatory risk for Unicycive Therapeutics, likely pressuring the stock lower.

    tipranks.com · Oct 28, 2026

  • Positive regulatory progress likely lifts the stock as approval odds improve.

    tradingview.com · Oct 21, 2026

  • Unicycive Therapeutics' average stock price target increased from $28.4 to $29.56 by 9 analysts, with a range of $13 to $42. This implies a 599% upside from the Oct. 6 closing price. The consensus rating remains 'Buy' with all 9 analysts recommending purchase.

    tradingview.com · Oct 7, 2026

AlphAI scores every news story that mentions UNCY with an AI model for sentiment and relevance, and aggregates insider trades from Unicycive Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $UNCY

Score

Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities

Unicycive Therapeutics reported a Q3 2026 net loss of $7.0 million, or $0.25 per share, with $59 million in cash. The FDA accepted its OLC NDA resubmission, setting a March 25, 2027 PDUFA date. The company expects its cash runway to extend beyond 2027, including potential OLC launch costs. Research and development expenses decreased to $2.2 million from $3.0 million a year earlier, while general and administrative expenses increased to $6.6 million from $4.4 million.

$UNCYMedEarnings

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update - New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (

$UNCYMedClinical / regulatory· NDA submission

Unicycive Therapeutics, Inc. (UNCY): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor - The resubmission package includes 12 month

Unicycive Therapeutics, Inc. Reports Material Event

Unicycive Therapeutics (UNCY) disclosed a securities class action lawsuit filed on September 3, 2026, in the Northern District of California. The lawsuit alleges violations of federal securities laws related to public statements about its oxylanthanum carbonate phosphate binder for treating hyperphosphatemia. The company states it believes the claims are meritless and plans to defend itself vigorously.

$UNCYMedAI 8/10

A securities class action lawsuit was filed in United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. and…

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events . On September 3, 2026, a securities class action lawsuit was filed in United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. (the “Company”) and certain of its officers. This action alleges violations of t

Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake

Unicycive Therapeutics, Inc. disclosed in an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC report beneficial ownership of 4,856,259 shares, or 9.99%, based on 27,855,257 shares outstanding as of Aug. 12, 2026. The stake includes 550,000 common shares plus conversion of Series A-3/A-4/A-5 preferred underlying warrants exercisable within 60 days.

Related tickers